CASI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters

May 16

CASI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

CASI Pharmaceuticals Inc CASI.OQ reported a quarterly adjusted loss of 69 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -71 cents. The lone analyst forecast for the quarter was for a loss of 61 cents per share.
Revenue rose 83% to $6.24 million from a year ago; analysts expected $6.10 million.
CASI Pharmaceuticals Inc's reported EPS for the quarter was a loss of 69 cents.
CASI Pharmaceuticals Inc shares had fallen by 16.2% this quarter and lost 36.0% so far this year.

FORECAST CHANGES

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for CASI Pharmaceuticals Inc is $4.00

This summary was machine generated from LSEG data May 16 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING	ESTIMATE	ACTUAL	BEAT, MET, MISSED
Mar. 31 2025	-0.61	-0.69	Missed
		-0.75
Sep. 30 2024	-0.62	-0.55	Beat
Jun. 30 2024	-0.63	-0.55	Beat

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2535631805"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535631805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535631805?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535631805","market":"nz","top_or_hot":-1,"title":"CASI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CASI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary</title></head><body><ul><li><p>CASI Pharmaceuticals Inc <span>CASI.OQ</span> reported a quarterly adjusted loss of 69 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -71 cents.  The lone analyst forecast for the quarter was for a loss of 61 cents per share. </p></li><li><p>Revenue rose 83% to $6.24 million from a year ago; analysts expected $6.10 million. </p></li><li><p>CASI Pharmaceuticals Inc's reported EPS for the quarter was a loss of 69 cents.</p></li><li><p>CASI Pharmaceuticals Inc shares had fallen by 16.2% this quarter and lost 36.0% so far this year.</p></li></ul><p>FORECAST CHANGES</p><ul><li><p>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p></li></ul><p>RECOMMENDATIONS</p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the pharmaceuticals peer group is also \"buy\" </p></li><li><p>Wall Street's median 12-month price target for CASI Pharmaceuticals Inc is $4.00 </p></li></ul><p>This summary was machine generated from LSEG data May 16 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td></tr><tr><td><p>Mar. 31 2025 </p></td><td><p>-0.61</p></td><td><p>-0.69</p></td><td><p>Missed</p></td></tr><tr><td></td><td></td><td><p>-0.75</p></td><td></td></tr><tr><td><p>Sep. 30 2024 </p></td><td><p>-0.62</p></td><td><p>-0.55</p></td><td><p>Beat</p></td></tr><tr><td><p>Jun. 30 2024 </p></td><td><p>-0.63</p></td><td><p>-0.55</p></td><td><p>Beat</p></td></tr></tbody></table></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CASI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCASI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-16 21:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CASI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary</title></head><body><ul><li><p>CASI Pharmaceuticals Inc <span>CASI.OQ</span> reported a quarterly adjusted loss of 69 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -71 cents.  The lone analyst forecast for the quarter was for a loss of 61 cents per share. </p></li><li><p>Revenue rose 83% to $6.24 million from a year ago; analysts expected $6.10 million. </p></li><li><p>CASI Pharmaceuticals Inc's reported EPS for the quarter was a loss of 69 cents.</p></li><li><p>CASI Pharmaceuticals Inc shares had fallen by 16.2% this quarter and lost 36.0% so far this year.</p></li></ul><p>FORECAST CHANGES</p><ul><li><p>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p></li></ul><p>RECOMMENDATIONS</p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the pharmaceuticals peer group is also \"buy\" </p></li><li><p>Wall Street's median 12-month price target for CASI Pharmaceuticals Inc is $4.00 </p></li></ul><p>This summary was machine generated from LSEG data May 16 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td></tr><tr><td><p>Mar. 31 2025 </p></td><td><p>-0.61</p></td><td><p>-0.69</p></td><td><p>Missed</p></td></tr><tr><td></td><td></td><td><p>-0.75</p></td><td></td></tr><tr><td><p>Sep. 30 2024 </p></td><td><p>-0.62</p></td><td><p>-0.55</p></td><td><p>Beat</p></td></tr><tr><td><p>Jun. 30 2024 </p></td><td><p>-0.63</p></td><td><p>-0.55</p></td><td><p>Beat</p></td></tr></tbody></table></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CASI","symbol_name":"凯信远达","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nL8N3RO12Y:1","article_id":"2535631805","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535631805","pubTimestamp":1747402331,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CASI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryCASI Pharmaceuticals Inc CASI.OQ reported a quarterly adjusted loss of 69 cents per share for the quarter ende","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CASI":"凯信远达"},"translate_title":"CASI Pharmaceuticals Inc报告截至3月31日的季度业绩-收益摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CASI":0.9},"content_text":"CASI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryCASI Pharmaceuticals Inc CASI.OQ reported a quarterly adjusted loss of 69 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -71 cents.  The lone analyst forecast for the quarter was for a loss of 61 cents per share. Revenue rose 83% to $6.24 million from a year ago; analysts expected $6.10 million. CASI Pharmaceuticals Inc's reported EPS for the quarter was a loss of 69 cents.CASI Pharmaceuticals Inc shares had fallen by 16.2% this quarter and lost 36.0% so far this year.FORECAST CHANGESIn the last 30 days, there have been no earnings estimate revisions by analysts covering the company.RECOMMENDATIONSThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the pharmaceuticals peer group is also \"buy\" Wall Street's median 12-month price target for CASI Pharmaceuticals Inc is $4.00 This summary was machine generated from LSEG data May 16 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)QUARTER ENDINGESTIMATE ACTUALBEAT, MET, MISSEDMar. 31 2025 -0.61-0.69Missed-0.75Sep. 30 2024 -0.62-0.55BeatJun. 30 2024 -0.63-0.55Beat","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}